Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

The latest international news, investigations and analysis from Africa, the Americas, Asia, Australia, Canada, Europe, the Middle East and the U.K.

Follow the latest Immigration news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to Immigration notifications.

The Santa Clarita Valley Signal is the #1 source for local news in the Santa Clarita Valley area since 1919.

The New York Times seeks the truth and helps people understand the world. With 1,700 journalists reporting from more than 150 countries, we provide live updates, investigations, photos and video ...